Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.77 USD
Change Today +0.24 / 6.80%
Volume 73.1K
CERU On Other Exchanges
As of 1:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

cerulean pharma inc (CERU) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/15 - $10.87
52 Week Low
08/17/15 - $2.77
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CERULEAN PHARMA INC (CERU)

Related News

No related news articles were found.

cerulean pharma inc (CERU) Related Businessweek News

No Related Businessweek News Found

cerulean pharma inc (CERU) Details

Cerulean Pharma Inc., a clinical-stage company, develops nanopharmaceutical product candidates in the areas of oncology and other diseases in the United States. The company’s lead product candidate is CRLX101, a tumor targeted nanoparticle-drug conjugate (NDC), which is in Phase II clinical trials for the treatment of relapsed renal cell carcinoma and relapsed ovarian cancer; and in Phase Ib clinical trials for the treatment of neoadjuvant rectal cancer, as well as in Phase II clinical trials for other indications, such as gastric cancer and small cell lung cancer. It is also developing CRLX301, a platform-generated clinical candidate, which is in Phase I clinical development for the treatment of tumor-targeted NDC. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Cambridge, Massachusetts.

39 Employees
Last Reported Date: 04/7/15
Founded in 2005

cerulean pharma inc (CERU) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $432.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $407.9K
Compensation as of Fiscal Year 2014.

cerulean pharma inc (CERU) Key Developments

Cerulean Pharma Inc. to Report Q2, 2015 Results on Aug 06, 2015

Cerulean Pharma Inc. announced that they will report Q2, 2015 results on Aug 06, 2015

Cerulean Pharma Inc., Q2 2015 Earnings Call, Aug 06, 2015

Cerulean Pharma Inc., Q2 2015 Earnings Call, Aug 06, 2015

Cerulean Pharma Inc. Announces First Patient in Phase 1b Trial of CRLX101 in Combination with Weekly Paclitaxel in Relapsed Ovarian Cancer

Cerulean Pharma Inc. announced that the first patient has been dosed in an open label Phase 1b clinical trial of its lead product candidate, CRLX101, in combination with weekly paclitaxel in patients with relapsed ovarian cancer by the University of Virginia School of Medicine. This trial is being conducted by Cerulean in collaboration with the GOG Foundation under the direction of principal investigator, Carolyn N. Krasner, M.D., of the Massachusetts General Hospital Cancer Center. Paclitaxel, a widely used chemotherapy used as subsequent therapy for the treatment of advanced ovarian cancer, has anti-angiogenic properties which can induce hypoxic conditions, to the up-regulation of hypoxia inducible factor 1a, or HIF-1a, causing tumors to develop drug resistance.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERU:US $3.77 USD +0.24

CERU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CERU.
View Industry Companies

Industry Analysis


Industry Average

Valuation CERU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERULEAN PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at